Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Autor: Joanna Bougie, Emmanouil Rampakakis, Maia Miguelez, Sally Mustafa, Jean Proulx, Ashok Malla, Guerline Clerzius
Rok vydání: 2019
Předmět:
Adult
Male
Canada
medicine.medical_specialty
Adolescent
lcsh:RC435-571
Global Assessment of Functioning
Aripiprazole
Weight Gain
Akathisia
Drug Administration Schedule
law.invention
Cohort Studies
Young Adult
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
lcsh:Psychiatry
Internal medicine
Brief Psychiatric Rating Scale
medicine
Humans
Prospective Studies
030212 general & internal medicine
Prospective cohort study
Aripiprazole once-monthly
business.industry
Long acting injectable antipsychotics
Middle Aged
medicine.disease
Global functioning
030227 psychiatry
Psychiatry and Mental health
Treatment Outcome
Adherence
Schizophrenia
Female
Schizophrenic Psychology
medicine.symptom
business
Antipsychotic Agents
Follow-Up Studies
Research Article
medicine.drug
Diagnosis of schizophrenia
Zdroj: BMC Psychiatry, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Psychiatry
ISSN: 1471-244X
DOI: 10.1186/s12888-019-2103-x
Popis: Background With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current study was designed to evaluate its effectiveness in patients treated for schizophrenia in regular clinical settings in Canada. Methods Following their clinicians’ decision to prescribe AOM, 193 patients with a diagnosis of schizophrenia, were recruited from 17 Canadian community or hospital-based settings. The primary outcome of global functioning was assessed with the Global Assessment of Functioning Scale (GAF) at 3-month intervals for 1 year. Secondary outcomes (social and occupational functioning and illness severity) and adverse drug reactions (ADR) were also assessed. Results A majority of the 169 evaluable patients were within the first 5 years of diagnosis (early phase). A linear mixed model analysis showed a significant main effect of time (Type III test p
Databáze: OpenAIRE
Externí odkaz: